Cardiovascular
Stealth and Pharmanovia partner for commercialisation of elamipretide
Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome.…
Lexicon gets FDA approval for Inpefa to treat heart failure
Lexicon Pharmaceuticals (Lexicon) has received approval from the US Food and Drug Administration (FDA) for its Inpefa drug to treat…
UK’s NICE recommends dapagliflozin to treat chronic heart failure
The UK’s National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending AstraZeneca’s dapagliflozin (Forxiga) to…
SERB Pharmaceuticals acquires US rights for bentracimab from SFJ
Speciality pharmaceutical company SERB Pharmaceuticals has acquired exclusive US rights for bentracimab from SFJ Pharmaceuticals. SFJ Pharmaceuticals will lead the…
FDA approves AstraZeneca’s Farxiga to cut CV deaths and hospitalisations
The US Food and Drug Administration (FDA) has granted approval for AstraZeneca’s Farxiga (dapagliflozin) to reduce the risks of cardiovascular…
Tenaya’s cardiomyopathy gene therapy gets fast track boost
The US Food and Drug Administration (FDA) has granted Tenaya Therapeutics’ gene therapy TN-201 a fast track designation for the…
China’s NMPA accepts LianBio’s NDA for oHCM therapy mavacamten
China’s National Medical Products Administration (NMPA) has accepted LianBio’s new drug application (NDA) for mavacamten, intended to treat symptomatic obstructive…
Hasten Biopharmaceutic raises $315m for pipeline assets development
Chinese firm Hasten Biopharmaceutic has raised $315m for business development of its pipeline assets in a financing round co-led by…
Israel Ministry of Health grants approval to Amarin’s Vazkepa
Israel Ministry of Health (MOH) Pharmaceuticals Division has granted regulatory approval to Amarin’s Vazkepa (icosapent ethyl) for reducing the risk…
Patent wars: What’s behind Amgen’s possible win over Sanofi at the US Supreme Court
Amgen could be the winner of a high-stakes patent spat with Sanofi as tensions run high weeks before the March…